{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:00:24Z","timestamp":1791511224712,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AI119187"],"award-info":[{"award-number":["AI119187"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH training","award":["T32 GM008804"],"award-info":[{"award-number":["T32 GM008804"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.antiviral.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T22:44:32Z","timestamp":1469832272000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in\u00a0vitro genetic barrier of drug resistance"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-8189","authenticated-orcid":false,"given":"Chunlong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami Ghassan","family":"Musharrafieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.07.019_bib1","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1128\/JVI.70.8.5170-5176.1996","article-title":"Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A","volume":"70","author":"Braaten","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/anie.201205674","article-title":"N-Methylation of peptides and proteins: an important element for modulating biological functions","volume":"52","author":"Chatterjee","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.antiviral.2016.07.019_bib3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/cmi.12108","article-title":"The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance","volume":"15","author":"Ehrhardt","year":"2013","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib4","first-page":"1","article-title":"Centers for Disease control and prevention, advisory committee on immunization practices 2008. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Fiore","year":"2008","journal-title":"MMWR. Recomm. Rep."},{"key":"10.1016\/j.antiviral.2016.07.019_bib5","first-page":"911","article-title":"Cyclophilin inhibitors for the treatment of HCV infection","volume":"11","author":"Fischer","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm400887j","article-title":"Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?","volume":"57","author":"Giordanetto","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/irv.12044","article-title":"Consequences of resistance: in\u00a0vitro fitness, in\u00a0vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses","volume":"7","author":"Govorkova","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7883\/yoken.66.276","article-title":"Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle","volume":"66","author":"Hamamoto","year":"2013","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1128\/JCM.43.8.4139-4146.2005","article-title":"Enhanced expression of an \u03b12,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor","volume":"43","author":"Hatakeyama","year":"2005","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.019_bib11","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.antiviral.2016.07.019_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2165\/11531450-000000000-00000","article-title":"Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses","volume":"69","author":"Hurt","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9120(91)90105-N","article-title":"Cyclosporine analogues","volume":"24","author":"Jeffery","year":"1991","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.antiviral.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.07.019_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","article-title":"Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection","volume":"96","author":"Lee","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2174\/0929867322666150227153919","article-title":"Inhibitors targeting the influenza virus hemagglutinin","volume":"22","author":"Li","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acs.jmedchem.5b01910","article-title":"Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"59","author":"Li","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"Lin","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.07.019_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2016.07.019_bib23","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib24","doi-asserted-by":"crossref","first-page":"e37277","DOI":"10.1371\/journal.pone.0037277","article-title":"Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.07.019_bib25","first-page":"1","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","author":"Loregian","year":"2014","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.antiviral.2016.07.019_bib26","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/jm4007577","article-title":"Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147","volume":"56","author":"Malesevic","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib27","series-title":"Influenza Pandemics: History and Lessons Learned, Textbook of Influenza","first-page":"20","author":"Monto","year":"2013"},{"key":"10.1016\/j.antiviral.2016.07.019_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrg2053","article-title":"The evolution of epidemic influenza","volume":"8","author":"Nelson","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.antiviral.2016.07.019_bib29","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1021\/jm9008295","article-title":"Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using de Novo Drug Design Approach","volume":"52","author":"Ni","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.019_bib32","first-page":"384","article-title":"Chapter 11 optimization of cyclophilin inhibitors for use in antiviral therapy, successful strategies for the discovery of antiviral drugs","author":"Peel","year":"2013","journal-title":"R.\u00a0Soc. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib33","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1016\/j.bmcl.2013.05.101","article-title":"Cyclophilin inhibitors as antiviral agents","volume":"23","author":"Peel","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2016.07.019_bib34","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.bbagen.2015.02.008","article-title":"Semi-synthesis of cyclosporins","volume":"1850","author":"Peel","year":"2015","journal-title":"Biochim. Biophys. Acta (BBA) - General Subj."},{"key":"10.1016\/j.antiviral.2016.07.019_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2011.05.019","article-title":"Emerging oseltamivir resistance in seasonal and pandemic influenza A\/H1N1","volume":"52","author":"Renaud","year":"2011","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.antiviral.2016.07.019_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/dkp393","article-title":"BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses","volume":"65","author":"Shih","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.07.019_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbapap.2012.02.002","article-title":"HIV-1 p6-Another viral interaction partner to the host cellular protein cyclophilin A","volume":"1824","author":"Solbak","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2016.07.019_bib39","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/jm500223x","article-title":"From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds","volume":"57","author":"Sweeney","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.019_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/JVI.00328-07","article-title":"Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein","volume":"82","author":"Tellinghuisen","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib41","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm910","article-title":"Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors","volume":"9","author":"Towers","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.07.019_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fvl.15.95","article-title":"M2 as a target to combat influenza drug resistance: what does the evidence say?","volume":"11","author":"Wang","year":"2015","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2016.07.019_bib43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1216526110","article-title":"Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.019_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bip.22623","article-title":"Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses","volume":"104","author":"Wang","year":"2015","journal-title":"Pept. Sci."},{"key":"10.1016\/j.antiviral.2016.07.019_bib46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2016.07.019_bib47","doi-asserted-by":"crossref","first-page":"17987","DOI":"10.1021\/ja508461m","article-title":"Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza a virus M2 proton channel","volume":"136","author":"Wu","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2016.07.019_bib48","doi-asserted-by":"crossref","first-page":"43202","DOI":"10.1074\/jbc.M305414200","article-title":"Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression","volume":"278","author":"Zander","year":"2003","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:25:23Z","timestamp":1600961123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216301486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":46,"alternative-id":["S0166354216301486"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.019","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in\u00a0vitro genetic barrier of drug resistance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}